search
Back to results

Optimum Thiamine Intervention (OpTIn) Trial (OpTIn)

Primary Purpose

Wernicke-Korsakoff Syndrome

Status
Completed
Phase
Phase 4
Locations
Australia
Study Type
Interventional
Intervention
Thiamine Hydrochloride
Sponsored by
Menzies School of Health Research
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Wernicke-Korsakoff Syndrome focused on measuring Neurological, Diet and Nutrition, Mental Health

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Aged range 18-65 years
  • History of heavy alcohol use AUDIT-C score >4 or consumption >60mg/day or >80mg/binge

Exclusion Criteria:

  • Pregnant women
  • Under the age of 18 or over 65 years old
  • Known pre-existing neurological or cognitive impairment unrelated to thiamine deficiency or WKS
  • Renal dialysis patients
  • Sedated patients in ICU

Sites / Locations

  • Alice Springs Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

Acute Symptomatic WKS- 300mg

Acute Symptomatic WKS - 900mg

Acute Symptomatic WKS - 1500mg

High-risk subclinical WKS- 100mg

High-risk subclinical WKS- 300mg

High-risk subclinical WKS - 900mg

Arm Description

Thiamine Hydrochloride 300mg daily (i.e. 100mg 3 times/day) for 5 days

Thiamine Hydrochloride 900mg daily (i.e. 300mg 3 times/day) for 5 days

Thiamine Hydrochloride 1500mg daily (i.e. 500mg 3 times/day) for 5 days.

Thiamine Hydrochloride 100mg once daily for 3 days.

Thiamine Hydrochloride 300mg (i.e. 100mg 3 time/day) for 3 days

Thiamine Hydrochloride 900mg daily (i.e. 300mg 3 times/day) for 3 days.

Outcomes

Primary Outcome Measures

Standardised Cognitive assessment - RUDAS
Evaluate differences in cognitive outcomes among acute symptomatic WKS patients under three parenteral thiamine treatment conditions (300mg/day for 5 days, versus 900mg/day for 5 days, versus 1500mg/day for 5 days); and among patients at high risk of subclinical WKS-related brain damage under three parenteral thiamine treatment conditions (100mg/day for 3 days, versus 300mg/day for 3 days, versus 900mg/day for 3 days); using Standardised cognitive assessment - Rowland Universal Dementia Assessment Scale (RUDAS).
Standardised Cognitive assessment - CogState
Evaluate differences in cognitive outcomes among acute symptomatic WKS patients under three parenteral thiamine treatment conditions (300mg/day for 5 days, versus 900mg/day for 5 days, versus 1500mg/day for 5 days); and among patients at high risk of subclinical WKS-related brain damage under three parenteral thiamine treatment conditions (100mg/day for 3 days, versus 300mg/day for 3 days, versus 900mg/day for 3 days); using CogState battery.
Standardised Cognitive assessment - Story Memory Recall Test
Evaluate differences in cognitive outcomes among acute symptomatic WKS patients under three parenteral thiamine treatment conditions (300mg/day for 5 days, versus 900mg/day for 5 days, versus 1500mg/day for 5 days); and among patients at high risk of subclinical WKS-related brain damage under three parenteral thiamine treatment conditions (100mg/day for 3 days, versus 300mg/day for 3 days, versus 900mg/day for 3 days); using Story Memory Recall test
Standardised neurological examination
Evaluate differences in neurological outcomes among acute symptomatic WKS patients under three parenteral thiamine treatment conditions (300mg/day for 5 days, versus 900mg/day for 5 days, versus 1500mg/day for 5 days);and among patients at high-risk of subclinical WKS-related brain damage under three parenteral thiamine treatment conditions (100mg/day for 3 days, versus 300mg/day for 3 days, versus 900mg/day for 3 days); Using Standardised neurological examination. Aggregated as either normal or abnormal.

Secondary Outcome Measures

Blood thiamine levels
Correlate changes in red cell thiamine test results (blood test) with cognitive (standardised cognitive assessments score) and neurological functioning (standardised neurological examination).
Magnesium levels
Examine the impact of magnesium deficiency (magnesium blood test) on thiamine treatment response (cognition as measured by standardised cognitive assessments and thiamine pyrophosphate levels as measured by blood test).
Demographic factors
Assess independent predictors of WKS including nutritional factors, substance use history and demographic factors assessed by questionnaire items including Nutritional Risk Assessment and AUDIT-C.
Readmission
Examine the impact of patient re-admission on red cell thiamine pyrophosphate levels (blood test) and cognitive and neurological functioning (standardised cognitive and neurological assessments)

Full Information

First Posted
September 26, 2014
Last Updated
August 15, 2019
Sponsor
Menzies School of Health Research
search

1. Study Identification

Unique Protocol Identification Number
NCT02788552
Brief Title
Optimum Thiamine Intervention (OpTIn) Trial
Acronym
OpTIn
Official Title
Optimum Thiamine Intervention (OpT In) for Treatment and Prevention of Wernicke-Korsakoff Syndrome (WKS): A Randomised Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2019
Overall Recruitment Status
Completed
Study Start Date
September 2014 (undefined)
Primary Completion Date
May 30, 2019 (Actual)
Study Completion Date
August 1, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Menzies School of Health Research

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Wernicke-Korsakoff syndrome (WKS), once thought to be a rare condition, is now known to be common in people with nutritional deficiencies or alcohol dependence. The primary cause of WKS is thiamine deficiency, and more than 90% of cases are reported in alcohol dependent patients because alcohol dependence predisposes to severe nutritional deficiency. WKS may lead to significant, long-term brain dysfunction with severe effects on work, personal and social function. Whilst effective treatment may greatly reduce severe disability and the human and social costs of this illness, almost no evidence exists on optimal dosing regimens. This project proposes to develop quality evidence for effective treatment of WKS in an Aboriginal setting.
Detailed Description
Wernicke-Korsakoff syndrome (WKS), once thought to be a rare condition, is now known to be common in people with nutritional deficiencies or alcohol dependence. The primary cause of WKS is thiamine deficiency, and more than 90% of cases are reported in alcohol dependent patients because alcohol dependence predisposes to severe nutritional deficiency. WKS may lead to significant, long-term brain dysfunction with severe effects on work, personal and social function. Whilst effective treatment may greatly reduce severe disability and the human and social costs of this illness, almost no evidence exists on optimal dosing regimens. This project proposes to develop quality evidence for effective treatment of WKS in an Aboriginal setting.. The need for evidence-based thiamine treatment protocols is of great clinical importance for two related reasons. First, in relation to acute symptomatic WKS, a failure to treat immediately or adequately may result in profound and often permanent cognitive and neurological disability. Secondly, the need for evidence-based treatment guidelines is greatly magnified when it is recognised that milder, subclinical WKS may be preventable with adequate thiamine treatment. The aims of this study are to determine the optimal thiamine dose required for: A. Treatment of acute symptomatic WKS among Aboriginal and non-Aboriginal alcohol dependent patients. B. Reducing or preventing subclinical WKS-related brain damage in at-risk Aboriginal and non-Aboriginal alcohol-dependent patients. Primary Hypotheses Among alcohol-dependent patients with acute symptomatic WKS, higher doses of parenteral thiamine (1500mg) will lead to greater improvements in specific cognition and neurological functions than lower doses (900mg or 300mg). Among alcohol-dependent patients that are at high risk for subclinical WKS-related brain damage, higher doses of parenteral thiamine (900mg) will lead to greater improvements in specific cognition and neurological functions compared to lower doses (300mg or 100mg). Secondary Hypotheses Thiamine deficient patients will show poorer performance on cognitive and neurological measures. Patients with concurrent magnesium deficiency will show greater impairment at baseline. Nutritional risk and alcohol frequency will correlate with thiamine pyrophosphate levels. Number of previous admissions with thiamine supplementation in the past 3 months will correlate with thiamine pyrophosphate levels

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Wernicke-Korsakoff Syndrome
Keywords
Neurological, Diet and Nutrition, Mental Health

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
334 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Acute Symptomatic WKS- 300mg
Arm Type
Active Comparator
Arm Description
Thiamine Hydrochloride 300mg daily (i.e. 100mg 3 times/day) for 5 days
Arm Title
Acute Symptomatic WKS - 900mg
Arm Type
Active Comparator
Arm Description
Thiamine Hydrochloride 900mg daily (i.e. 300mg 3 times/day) for 5 days
Arm Title
Acute Symptomatic WKS - 1500mg
Arm Type
Active Comparator
Arm Description
Thiamine Hydrochloride 1500mg daily (i.e. 500mg 3 times/day) for 5 days.
Arm Title
High-risk subclinical WKS- 100mg
Arm Type
Active Comparator
Arm Description
Thiamine Hydrochloride 100mg once daily for 3 days.
Arm Title
High-risk subclinical WKS- 300mg
Arm Type
Active Comparator
Arm Description
Thiamine Hydrochloride 300mg (i.e. 100mg 3 time/day) for 3 days
Arm Title
High-risk subclinical WKS - 900mg
Arm Type
Active Comparator
Arm Description
Thiamine Hydrochloride 900mg daily (i.e. 300mg 3 times/day) for 3 days.
Intervention Type
Drug
Intervention Name(s)
Thiamine Hydrochloride
Other Intervention Name(s)
Vitamin B1, Thiamine Chloride, Aneurine Hydrochloride, B Complex Vitamin
Intervention Description
Administered Intravenously in 100ml bag of normal saline (0.9%) infused over 30 mins.
Primary Outcome Measure Information:
Title
Standardised Cognitive assessment - RUDAS
Description
Evaluate differences in cognitive outcomes among acute symptomatic WKS patients under three parenteral thiamine treatment conditions (300mg/day for 5 days, versus 900mg/day for 5 days, versus 1500mg/day for 5 days); and among patients at high risk of subclinical WKS-related brain damage under three parenteral thiamine treatment conditions (100mg/day for 3 days, versus 300mg/day for 3 days, versus 900mg/day for 3 days); using Standardised cognitive assessment - Rowland Universal Dementia Assessment Scale (RUDAS).
Time Frame
Days 1 and 5 for Acute symptomatic patients and Days 1 and 3 for at risk patients
Title
Standardised Cognitive assessment - CogState
Description
Evaluate differences in cognitive outcomes among acute symptomatic WKS patients under three parenteral thiamine treatment conditions (300mg/day for 5 days, versus 900mg/day for 5 days, versus 1500mg/day for 5 days); and among patients at high risk of subclinical WKS-related brain damage under three parenteral thiamine treatment conditions (100mg/day for 3 days, versus 300mg/day for 3 days, versus 900mg/day for 3 days); using CogState battery.
Time Frame
Days 1 and 5 for Acute symptomatic patients and Days 1 and 3 for at risk patients
Title
Standardised Cognitive assessment - Story Memory Recall Test
Description
Evaluate differences in cognitive outcomes among acute symptomatic WKS patients under three parenteral thiamine treatment conditions (300mg/day for 5 days, versus 900mg/day for 5 days, versus 1500mg/day for 5 days); and among patients at high risk of subclinical WKS-related brain damage under three parenteral thiamine treatment conditions (100mg/day for 3 days, versus 300mg/day for 3 days, versus 900mg/day for 3 days); using Story Memory Recall test
Time Frame
Days 1 and 5 for Acute symptomatic patients and Days 1 and 3 for at risk patients
Title
Standardised neurological examination
Description
Evaluate differences in neurological outcomes among acute symptomatic WKS patients under three parenteral thiamine treatment conditions (300mg/day for 5 days, versus 900mg/day for 5 days, versus 1500mg/day for 5 days);and among patients at high-risk of subclinical WKS-related brain damage under three parenteral thiamine treatment conditions (100mg/day for 3 days, versus 300mg/day for 3 days, versus 900mg/day for 3 days); Using Standardised neurological examination. Aggregated as either normal or abnormal.
Time Frame
Days 1 and 5 for acute symptomatic patients; Days 1 and 3 for at risk patients
Secondary Outcome Measure Information:
Title
Blood thiamine levels
Description
Correlate changes in red cell thiamine test results (blood test) with cognitive (standardised cognitive assessments score) and neurological functioning (standardised neurological examination).
Time Frame
Days 1 and 5 for acute symptomatic patients; days 1 and 3 for at risk patients
Title
Magnesium levels
Description
Examine the impact of magnesium deficiency (magnesium blood test) on thiamine treatment response (cognition as measured by standardised cognitive assessments and thiamine pyrophosphate levels as measured by blood test).
Time Frame
Days 1 and 5 for acute symptomatic patients; Days 1 and 3 for at risk patients
Title
Demographic factors
Description
Assess independent predictors of WKS including nutritional factors, substance use history and demographic factors assessed by questionnaire items including Nutritional Risk Assessment and AUDIT-C.
Time Frame
Day 1
Title
Readmission
Description
Examine the impact of patient re-admission on red cell thiamine pyrophosphate levels (blood test) and cognitive and neurological functioning (standardised cognitive and neurological assessments)
Time Frame
Day 1

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged range 18-65 years History of heavy alcohol use AUDIT-C score >4 or consumption >60mg/day or >80mg/binge Exclusion Criteria: Pregnant women Under the age of 18 or over 65 years old Known pre-existing neurological or cognitive impairment unrelated to thiamine deficiency or WKS Renal dialysis patients Sedated patients in ICU
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kylie Dingwall, PhD
Organizational Affiliation
Menzies School of Health Research
Official's Role
Principal Investigator
Facility Information:
Facility Name
Alice Springs Hospital
City
Alice Springs
State/Province
Northern Territory
ZIP/Postal Code
0810
Country
Australia

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Optimum Thiamine Intervention (OpTIn) Trial

We'll reach out to this number within 24 hrs